BeOne Medicines (formerly known as BeiGene) is a biotechnology company that discovers and develops oncology treatments. It focuses on targeted and immuno-oncology drugs that address unmet medical needs in a variety of cancer indications. Its products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2.